Insulet Debt to Equity Ratio 2010-2025 | PODD
Current and historical debt to equity ratio values for Insulet (PODD) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Insulet debt/equity for the three months ending March 31, 2025 was 1.21.
| Insulet Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $2.19B | $1.33B | 1.64 |
| 2024-12-31 | $1.88B | $1.21B | 1.55 |
| 2024-09-30 | $1.91B | $1.12B | 1.71 |
| 2024-06-30 | $1.88B | $1.00B | 1.89 |
| 2024-03-31 | $1.83B | $0.79B | 2.32 |
| 2023-12-31 | $1.86B | $0.73B | 2.53 |
| 2023-09-30 | $1.86B | $0.61B | 3.06 |
| 2023-06-30 | $1.83B | $0.55B | 3.31 |
| 2023-03-31 | $1.79B | $0.50B | 3.55 |
| 2022-12-31 | $1.78B | $0.48B | 3.73 |
| 2022-09-30 | $1.74B | $0.43B | 4.06 |
| 2022-06-30 | $1.69B | $0.42B | 4.00 |
| 2022-03-31 | $1.62B | $0.45B | 3.63 |
| 2021-12-31 | $1.49B | $0.56B | 2.68 |
| 2021-09-30 | $1.50B | $0.50B | 3.02 |
| 2021-06-30 | $1.47B | $0.46B | 3.19 |
| 2021-03-31 | $1.26B | $0.59B | 2.14 |
| 2020-12-31 | $1.27B | $0.60B | 2.10 |
| 2020-09-30 | $1.12B | $0.60B | 1.88 |
| 2020-06-30 | $1.06B | $0.56B | 1.89 |
| 2020-03-31 | $1.05B | $0.06B | 17.78 |
| 2019-12-31 | $1.07B | $0.08B | 14.06 |
| 2019-09-30 | $1.12B | $0.15B | 7.42 |
| 2019-06-30 | $0.73B | $0.25B | 2.91 |
| 2019-03-31 | $0.73B | $0.22B | 3.26 |
| 2018-12-31 | $0.72B | $0.21B | 3.38 |
| 2018-09-30 | $0.69B | $0.20B | 3.48 |
| 2018-06-30 | $0.66B | $0.18B | 3.68 |
| 2018-03-31 | $0.66B | $0.17B | 3.87 |
| 2017-12-31 | $0.66B | $0.16B | 4.15 |
| 2017-09-30 | $0.43B | $0.07B | 5.74 |
| 2017-06-30 | $0.40B | $0.07B | 6.10 |
| 2017-03-31 | $0.38B | $0.06B | 6.00 |
| 2016-12-31 | $0.39B | $0.06B | 6.23 |
| 2016-09-30 | $0.39B | $0.07B | 5.96 |
| 2016-06-30 | $0.24B | $0.03B | 8.59 |
| 2016-03-31 | $0.23B | $0.03B | 8.65 |
| 2015-12-31 | $0.24B | $0.03B | 7.08 |
| 2015-09-30 | $0.24B | $0.06B | 4.32 |
| 2015-06-30 | $0.23B | $0.07B | 3.28 |
| 2015-03-31 | $0.23B | $0.08B | 2.79 |
| 2014-12-31 | $0.21B | $0.08B | 2.55 |
| 2014-09-30 | $0.22B | $0.08B | 2.75 |
| 2014-06-30 | $0.25B | $0.08B | 3.18 |
| 2014-03-31 | $0.17B | $0.12B | 1.36 |
| 2013-12-31 | $0.16B | $0.13B | 1.31 |
| 2013-09-30 | $0.17B | $0.12B | 1.38 |
| 2013-06-30 | $0.15B | $0.14B | 1.07 |
| 2013-03-31 | $0.15B | $0.13B | 1.17 |
| 2012-12-31 | $0.15B | $0.04B | 3.48 |
| 2012-09-30 | $0.15B | $0.05B | 3.03 |
| 2012-06-30 | $0.15B | $0.06B | 2.45 |
| 2012-03-31 | $0.15B | $0.07B | 2.07 |
| 2011-12-31 | $0.14B | $0.08B | 1.68 |
| 2011-09-30 | $0.13B | $0.08B | 1.59 |
| 2011-06-30 | $0.13B | $0.09B | 1.40 |
| 2011-03-31 | $0.09B | $0.06B | 1.49 |
| 2010-12-31 | $0.09B | $0.07B | 1.36 |
| 2010-09-30 | $0.12B | $0.03B | 3.47 |
| 2010-06-30 | $0.12B | $0.04B | 2.68 |
| 2010-03-31 | $0.12B | $0.04B | 2.89 |
| 2009-12-31 | $0.11B | $0.06B | 1.79 |
| 2009-09-30 | $0.12B | $0.00B | 385.56 |
| 2009-06-30 | $0.10B | $0.00B | -29.61 |
| 2009-03-31 | $0.10B | $0.02B | 6.75 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $20.361B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.693B | 27.62 |
| Boston Scientific (BSX) | United States | $152.679B | 38.22 |
| Stryker (SYK) | United States | $148.653B | 31.08 |
| EssilorLuxottica (ESLOY) | France | $131.422B | 0.00 |
| Medtronic (MDT) | Ireland | $115.326B | 16.35 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.078B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.743B | 25.54 |
| ResMed (RMD) | United States | $37.302B | 28.02 |
| Agilent Technologies (A) | United States | $35.020B | 22.83 |
| GE HealthCare Technologies (GEHC) | United States | $34.401B | 16.33 |
| Terumo (TRUMY) | Japan | $24.607B | 31.96 |
| Koninklijke Philips (PHG) | Netherlands | $23.139B | 16.24 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.556B | 11.92 |
| Baxter (BAX) | United States | $14.728B | 11.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.262B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.993B | 24.33 |
| Lantheus Holdings (LNTH) | United States | $5.626B | 14.19 |
| Perrigo (PRGO) | Ireland | $3.785B | 9.59 |
| Prestige Consumer Healthcare (PBH) | United States | $3.780B | 16.89 |
| Haemonetics (HAE) | United States | $3.628B | 16.53 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.424B | 28.45 |
| ICU Medical (ICUI) | United States | $3.253B | 23.99 |
| QuidelOrtho (QDEL) | United States | $2.052B | 14.11 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 42.27 |
| AtriCure (ATRC) | United States | $1.521B | 0.00 |
| Acuren (TIC) | United States | $1.395B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.389B | 31.24 |
| Phibro Animal Health (PAHC) | United States | $1.248B | 15.96 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Neogen (NEOG) | United States | $1.170B | 14.97 |
| BioLife Solutions (BLFS) | United States | $1.050B | 0.00 |
| InMode (INMD) | Israel | $0.930B | 9.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.771B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.766B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.695B | 0.00 |
| Owens & Minor (OMI) | United States | $0.627B | 5.21 |
| Evolus (EOLS) | United States | $0.611B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.584B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.517B | 0.00 |
| Surmodics (SRDX) | United States | $0.441B | 0.00 |
| SNDL (SNDL) | Canada | $0.365B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.349B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.38 |
| Cresco Labs (CRLBF) | United States | $0.323B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.298B | 0.00 |
| Quanterix (QTRX) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.47 |
| Sanara MedTech (SMTI) | United States | $0.258B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.83 |
| ZimVie (ZIMV) | United States | $0.251B | 11.39 |
| Verano Holdings (VRNOF) | United States | $0.235B | 0.00 |
| Brainsway (BWAY) | Israel | $0.233B | 61.55 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Biote (BTMD) | United States | $0.223B | 6.28 |
| Omeros (OMER) | United States | $0.214B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| High Tide (HITI) | Canada | $0.191B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.93 |
| Vireo Growth (VREOF) | United States | $0.163B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.122B | 15.05 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| MacroGenics (MGNX) | United States | $0.102B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.68 |
| Jushi Holdings (JUSHF) | United States | $0.090B | 0.00 |
| Veru (VERU) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.081B | 0.00 |
| Apyx Medical (APYX) | United States | $0.079B | 0.00 |
| Agape ATP (ATPC) | $0.074B | 0.00 | |
| Zynex (ZYXI) | United States | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Nephros (NEPH) | United States | $0.038B | 51.43 |
| United-Guardian (UG) | United States | $0.037B | 12.89 |
| Safety Shot (SHOT) | United States | $0.034B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |